Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02299310

Enrollment

Registered

2014-11-24

Start date

2014-11-30

Completion date

2015-12-31

Last updated

2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

Chronic kidney disease, Anti-hypertensive drugs

Brief summary

The purpose of this study is to compare the effect of valsartan and perindopril on HOMA-IR Index in patients with chronic kidney disease.

Detailed description

eligiable volunteers are administrated single-dose over the period I and II (crossover) of Valsartan (80mg) as of Perindopril (4mg). Every time before and after each medication, HOMA-IR index and other parameters and safety of Valsartan (80mg) and Perindopril (4mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.

Interventions

DRUGValsartan

Valsartan 80mg/tablet, 1 tablet once daily (crossover)

DRUGPerindopril

Perindopril 4mg/tablet, 1 tablet once daily (crossover)

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of chronic kidney disease * Serum creatinine:1\ 3mg/dl

Exclusion criteria

* Diabetes * Patients treated with corticosteroids or immunosuppressants * BMI\>30kg/m2 * SP\>180mmHg, DP\>110mmHg * Patients with serious medical problems requiring specific medical treatment

Design outcomes

Primary

Measure	Time frame	Description
Homeostasis model of assessment for insulin resistence index (HOMA-IR index)	4 weeks	HOMA-IR=FINS\*FGLU/22.5

Secondary

Measure	Time frame	Description
Glomerular filtration rate(eGFR) and Creatinine clearance rate(CCR)	4 weeks	eGFR and CCR are calculated with MDRD formula
Body mass index(BMI)	4 weeks	BMI=weight/(height)\^2
24-h urine protein, urinary albumin-creatinin ration, retinol binding protein	4 weeks	—
Cholesterol, triglycerides, high density lipoprotein, low density lipoprotein	4 weeks	—
Glycosylated hemoglobin	4 weeks	—

Countries

China

Contacts

Primary ContactRiBao Wei, Master

wrbbj2006@126.com+861055499133

Backup ContactRui Wang, Master

wrbbj2014@126.com+861055499133

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026